Literature DB >> 27106062

RIG-I ligand enhances the immunogenicity of recombinant H7HA protein.

Weiping Cao1, Justine S Liepkalns2, Ram P Kamal3, Adrian J Reber2, Jin Hyang Kim2, Amelia R Hofstetter4, Samuel Amoah3, James Stevens5, Priya Ranjan2, Shivaprakash Gangappa2, Ian A York2, Suryaprakash Sambhara2.   

Abstract

Avian H7N9 influenza virus infection with fatal outcomes continues to pose a pandemic threat and highly immunogenic vaccines are urgently needed. In this report we show that baculovirus-derived recombinant H7 hemagglutinin protein, when delivered with RIG-I ligand, induced enhanced antibody and T cell responses and conferred protection against lethal challenge with a homologous H7N9 virus. These findings indicate the potential utility of RIG-I ligands as vaccine adjuvants to increase the immunogenicity of recombinant H7 hemagglutinin. Published by Elsevier Inc.

Entities:  

Keywords:  Antibody responses; Cell-mediated immunity; H7HA; Influenza; Mouse model; Protective immunity; RIG-I ligand

Mesh：

Substances：

Year:  2016        PMID： 27106062      PMCID： PMC5240151          DOI： 10.1016/j.cellimm.2016.04.004

Source DB:  PubMed          Journal:  Cell Immunol        ISSN： 0008-8749            Impact factor:   4.868


  19 in total

1.  Structural analysis of the hemagglutinin from the recent 2013 H7N9 influenza virus.

Authors:  Hua Yang; Paul J Carney; Jessie C Chang; Julie M Villanueva; James Stevens
Journal:  J Virol       Date:  2013-09-11       Impact factor: 5.103

2.  RIG-I detects viral genomic RNA during negative-strand RNA virus infection.

Authors:  Jan Rehwinkel; Choon Ping Tan; Delphine Goubau; Oliver Schulz; Andreas Pichlmair; Katja Bier; Nicole Robb; Frank Vreede; Wendy Barclay; Ervin Fodor; Caetano Reis e Sousa
Journal:  Cell       Date:  2010-02-05       Impact factor: 41.582

Review 3.  Innate immune pattern recognition: a cell biological perspective.

Authors:  Sky W Brubaker; Kevin S Bonham; Ivan Zanoni; Jonathan C Kagan
Journal:  Annu Rev Immunol       Date:  2015-01-02       Impact factor: 28.527

4.  Activation of the RIG-I pathway during influenza vaccination enhances the germinal center reaction, promotes T follicular helper cell induction, and provides a dose-sparing effect and protective immunity.

Authors:  Raveendra R Kulkarni; Mohammed Ata Ur Rasheed; Siddhartha Kumar Bhaumik; Priya Ranjan; Weiping Cao; Carl Davis; Krishna Marisetti; Sunil Thomas; Shivaprakash Gangappa; Suryaprakash Sambhara; Kaja Murali-Krishna
Journal:  J Virol       Date:  2014-09-24       Impact factor: 5.103

5.  Clinical testing of pre-pandemic live attenuated A/H5N2 influenza candidate vaccine in adult volunteers: results from a placebo-controlled, randomized double-blind phase I study.

Authors:  Larisa Rudenko; Irina Kiseleva; Marina Stukova; Marianna Erofeeva; Anatoly Naykhin; Svetlana Donina; Natalie Larionova; Maria Pisareva; Vera Krivitskaya; Jorge Flores
Journal:  Vaccine       Date:  2015-08-19       Impact factor: 3.641

6.  Increased risk of narcolepsy in children and adults after pandemic H1N1 vaccination in France.

Authors:  Yves Dauvilliers; Isabelle Arnulf; Michel Lecendreux; Christelle Monaca Charley; Patricia Franco; Xavier Drouot; Marie-Pia d'Ortho; Sandrine Launois; Séverine Lignot; Patrice Bourgin; Béatrice Nogues; Marc Rey; Sophie Bayard; Sabine Scholz; Sophie Lavault; Pascale Tubert-Bitter; Cristel Saussier; Antoine Pariente
Journal:  Brain       Date:  2013-08       Impact factor: 13.501

7.  5'PPP-RNA induced RIG-I activation inhibits drug-resistant avian H5N1 as well as 1918 and 2009 pandemic influenza virus replication.

Authors:  Priya Ranjan; Lakshmi Jayashankar; Varough Deyde; Hui Zeng; William G Davis; Melissa B Pearce; John B Bowzard; Mary A Hoelscher; Victoria Jeisy-Scott; Mayim E Wiens; Shivaprakash Gangappa; Larisa Gubareva; Adolfo García-Sastre; Jacqueline M Katz; Terrence M Tumpey; Takashi Fujita; Suryaprakash Sambhara
Journal:  Virol J       Date:  2010-05-21       Impact factor: 4.099

8.  A phase I clinical trial of a PER.C6 cell grown influenza H7 virus vaccine.

Authors:  Rebecca J Cox; Abdullah S Madhun; Solveig Hauge; Haakon Sjursen; Diane Major; Mirjam Kuhne; Katja Höschler; Melanie Saville; Frederick R Vogel; Wendy Barclay; Isabella Donatelli; Maria Zambon; John Wood; Lars R Haaheim
Journal:  Vaccine       Date:  2009-02-02       Impact factor: 3.641

9.  AS03 adjuvanted AH1N1 vaccine associated with an abrupt increase in the incidence of childhood narcolepsy in Finland.

Authors:  Hanna Nohynek; Jukka Jokinen; Markku Partinen; Outi Vaarala; Turkka Kirjavainen; Jonas Sundman; Sari-Leena Himanen; Christer Hublin; Ilkka Julkunen; Päivi Olsén; Outi Saarenpää-Heikkilä; Terhi Kilpi
Journal:  PLoS One       Date:  2012-03-28       Impact factor: 3.240

Review 10.  The pandemic potential of avian influenza A(H7N9) virus: a review.

Authors:  W D Tanner; D J A Toth; A V Gundlapalli
Journal:  Epidemiol Infect       Date:  2015-07-24       Impact factor: 4.434
View more
  2 in total

1.  Antibody Immunity Induced by H7N9 Avian Influenza Vaccines: Evaluation Criteria, Affecting Factors, and Implications for Rational Vaccine Design.

Authors:  Zenglei Hu; Xinan Jiao; Xiufan Liu
Journal:  Front Microbiol       Date:  2017-09-26       Impact factor: 5.640

2.  Recombinant hemagglutinin produced from Chinese Hamster Ovary (CHO) stable cell clones and a PELC/CpG combination adjuvant for H7N9 subunit vaccine development.

Authors:  Ting-Hsuan Chen; Wen-Chun Liu; I-Chen Chen; Chia-Chyi Liu; Ming-Hsi Huang; Jia-Tsrong Jan; Suh-Chin Wu
Journal:  Vaccine       Date:  2019-08-02       Impact factor: 3.641
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.